Diastolic Fractional Flow Reserve (DFR) Threshold for Deferring PCI
Use a DFR threshold of >0.89 to safely defer PCI in patients with intermediate coronary stenoses, as this correlates with the established FFR threshold of >0.80 and is associated with low rates of major adverse cardiac events.
Evidence-Based Threshold
The most recent and highest-quality guideline evidence establishes clear thresholds for physiological assessment:
- FFR >0.80 is the validated threshold for deferring PCI 1
- DFR correlates strongly with FFR with near-equivalent diagnostic accuracy (AUC 98%) 2
- DFR >0.89 corresponds to FFR >0.80 and is the appropriate cutoff for deferring intervention
Clinical Decision Algorithm
When to Defer PCI:
- DFR >0.89: Safely defer PCI with low MACE rates (4.05-4.12% at follow-up) 1
- FFR >0.80: Equivalent safety profile with 2-year MI rate of 0.2% and revascularization rate of 3.2% 1
When to Proceed with PCI:
- DFR ≤0.89: Consider revascularization
- FFR ≤0.75: Strong indication for PCI 2
- FFR 0.75-0.80: Gray zone requiring clinical judgment 2, 3
Diagnostic Performance of DFR
Recent research validates DFR as a reliable alternative to FFR:
- Strong correlation with FFR (r = 0.74-0.80) 4, 5, 6
- Diagnostic accuracy of 88-92% for predicting FFR ≤0.80 4, 5, 6
- Sensitivity 54%, Specificity 82% using DFR ≤0.89 cutoff 4
- Agreement with FFR strategy in 74% of lesions 4
Key Advantages of DFR
DFR offers practical benefits over traditional FFR:
- No adenosine required: Eliminates hyperemia induction, avoiding side effects and reducing cost 4, 6
- Shorter procedural time: Streamlines the assessment process
- Equivalent prognostic value: Full-cycle FFR and dFFR have similar diagnostic value 2
- Consistent across vessels: Strong correlation maintained in all coronary territories 6
Important Caveats
Gray Zone Considerations:
When DFR falls between 0.85-0.89 or FFR between 0.75-0.80, integrate additional factors:
- Clinical symptoms: Presence and severity of angina
- Lesion characteristics: Serial lesions or diffuse disease may benefit from pullback assessment 7
- Microvascular function: Consider CFR/IMR if available, as discordant FFR/CFR results affect prognosis 2
Vessel-Specific Nuances:
The LAD may exhibit lower FFR/DFR values for similar angiographic severity compared to non-LAD vessels 8. However, validation studies show DFR maintains strong correlation across all coronary arteries with no statistical differences between vessels 6.
Post-Deferral Outcomes:
Even with appropriate deferral (DFR >0.89 or FFR >0.80), approximately 18% of patients may require intervention during long-term follow-up 2. The deferred lesion becomes the culprit in 38% of subsequent MIs 2. This underscores the importance of optimal medical therapy and continued surveillance.
Clinical Context
The 2024 ESC Guidelines 7 and 2021 ACC/AHA/SCAI Guidelines 1 both provide Class I, Level A recommendations for FFR/iFR-guided revascularization decisions. DFR represents a validated, hyperemia-free alternative that maintains diagnostic accuracy while improving procedural efficiency 4, 5, 6.
For intermediate stenoses (40-70% diameter narrowing), physiological assessment with DFR or FFR significantly outperforms angiography alone, reducing MACE from 8.6% to 4.8% (HR 0.55,95% CI 0.43-0.7) 2. This benefit persists at long-term follow-up, with FFR-guided strategies showing sustained superiority over medical therapy alone 9, 10.